Gastroparesis vs. SIBO: How to Tell the Difference

Gastroparesis (delayed gastric emptying) and small intestinal bacterial overgrowth (SIBO) are two distinct gastrointestinal conditions that share a remarkably similar symptom profile. Both cause nausea, bloating, abdominal distension, early satiety, abdominal pain, and altered bowel habits. Both are common in patients with dysautonomia, diabetes, and connective tissue disorders. And both are frequently misdiagnosed or missed entirely.

Understanding the differences between gastroparesis and SIBO — and recognizing when both are present simultaneously — is essential for effective treatment. Treating one while missing the other often produces incomplete or no improvement.

What Is Gastroparesis?

Gastroparesis is a motility disorder characterized by delayed emptying of the stomach in the absence of mechanical obstruction. The stomach's ability to grind food and propel it into the small intestine is impaired, causing food to sit in the stomach longer than normal.

The most common causes are diabetic neuropathy (damage to the vagus nerve from chronic hyperglycemia), post-viral gastroparesis (following a viral infection, particularly in the context of dysautonomia), and idiopathic gastroparesis (no identifiable cause). It also occurs at elevated rates in patients with POTS, EDS, and other connective tissue/autonomic disorders.

What Is SIBO?

Small intestinal bacterial overgrowth (SIBO) is a condition in which bacteria that normally reside in the colon colonize the small intestine in abnormally high numbers. The small intestine normally contains relatively few bacteria (compared to the colon); when bacteria overgrow here, they ferment carbohydrates that should be absorbed before reaching the colon, producing hydrogen and/or methane gas.

SIBO is caused by disruption of the mechanisms that normally keep the small intestine relatively sterile: the migrating motor complex (MMC, the "housekeeping" contractions that sweep bacteria toward the colon between meals), gastric acid (which kills bacteria before they enter the small intestine), and the ileocecal valve (which prevents backflow of colonic bacteria). Conditions that impair any of these mechanisms — including gastroparesis, autonomic neuropathy, proton pump inhibitor use, and prior abdominal surgery — predispose to SIBO.

Overlapping Symptoms

Key Distinguishing Features

Timing of symptoms relative to meals:

• Gastroparesis symptoms typically worsen during and immediately after eating, as food accumulates in the stomach.
• SIBO symptoms often worsen 1–3 hours after eating, as bacteria ferment carbohydrates in the small intestine. The delay reflects the time it takes for food to reach the bacterial overgrowth site.

Vomiting:

• Vomiting is more prominent in gastroparesis and may involve food eaten hours earlier (a hallmark of delayed gastric emptying).
• Vomiting is less common in SIBO; when it occurs, it is usually soon after eating.

Bowel habits:

• Gastroparesis does not directly cause diarrhea or constipation (though it can cause constipation by slowing overall gut transit).
• SIBO commonly causes diarrhea (hydrogen-dominant SIBO) or constipation (methane-dominant SIBO, also called intestinal methanogen overgrowth or IMO).

Response to fasting:

• Gastroparesis symptoms often improve with fasting (the stomach has time to empty).
• SIBO symptoms may also improve with fasting but can persist due to ongoing bacterial activity.

Nutritional deficiencies:

• Both can cause malabsorption, but the pattern differs. SIBO specifically impairs absorption of fat-soluble vitamins (A, D, E, K), B12 (bacteria consume it), and iron. Gastroparesis causes broader caloric and protein malnutrition.

Diagnostic Testing

For gastroparesis: The gold standard is a gastric emptying scintigraphy (GES) — a nuclear medicine study where the patient eats a standardized meal containing a radioactive tracer, and gamma camera images are taken at 1, 2, and 4 hours to measure the percentage of the meal retained in the stomach. Delayed emptying at 4 hours (>10% retention) confirms gastroparesis.

Wireless motility capsule (SmartPill) and gastric emptying breath test are alternative diagnostic methods.

For SIBO: The most widely used test is the lactulose or glucose hydrogen/methane breath test. The patient drinks a solution of lactulose or glucose, and breath samples are collected every 20–30 minutes for 2–3 hours. Bacteria in the small intestine ferment the substrate and produce hydrogen and/or methane gas, which is exhaled. An early rise in hydrogen or methane (before the substrate reaches the colon) suggests SIBO.

Small intestinal aspirate and culture (obtained during upper endoscopy) is the gold standard for SIBO diagnosis but is invasive and rarely performed in clinical practice.

Why They Often Co-Occur

Gastroparesis and SIBO co-occur frequently because gastroparesis impairs the migrating motor complex (MMC) — the between-meal contractions that sweep bacteria from the small intestine toward the colon. When the MMC is impaired, bacteria accumulate in the small intestine, leading to SIBO.

Studies suggest that SIBO is present in 40–60% of gastroparesis patients. This high co-occurrence rate means that treating gastroparesis alone — without addressing SIBO — often produces incomplete symptom relief.

The relationship can also be bidirectional: SIBO-related inflammation may worsen gut motility, potentially worsening gastroparesis. Treating SIBO can sometimes improve gastric emptying in patients with both conditions.

Treatment Differences

Gastroparesis treatment:

• Dietary modification (small, frequent, low-fat, low-fiber meals)
• Prokinetic medications (metoclopramide, domperidone, erythromycin, prucalopride)
• Antiemetics for nausea management
• Gastric electrical stimulation (for refractory cases)
• Nutritional support (enteral feeding if oral intake is inadequate)

SIBO treatment:

• Antibiotic therapy: rifaximin (for hydrogen-dominant SIBO), rifaximin + neomycin or metronidazole (for methane-dominant SIBO/IMO). Typical course is 10–14 days.
• Herbal antimicrobials (allicin, berberine, oregano oil) as alternatives to antibiotics for some patients.
• Elemental diet (2–3 weeks of exclusive elemental formula) as an alternative to antibiotics.
• Prokinetic therapy to restore MMC function and prevent recurrence.
• Dietary modification (low-FODMAP diet reduces fermentable substrates that feed bacteria).

When both are present: Treatment typically addresses SIBO first (with antibiotics or herbal antimicrobials), then reassesses gastroparesis symptoms. In many patients, treating SIBO produces significant improvement in overall GI symptoms, making it easier to assess the true severity of gastroparesis. Prokinetic therapy is then used to address residual gastroparesis and to prevent SIBO recurrence.

When to Suspect Both Conditions

Consider testing for both gastroparesis and SIBO when:

• Standard gastroparesis treatment (dietary modification + prokinetics) produces incomplete symptom relief
• Bloating and distension are disproportionately severe relative to nausea and vomiting
• There is significant diarrhea or constipation alongside typical gastroparesis symptoms
• There are nutritional deficiencies consistent with malabsorption (B12, iron, fat-soluble vitamins)
• The patient has risk factors for both conditions (diabetes, POTS, EDS, prior abdominal surgery, long-term PPI use)